A clue to a deal, page-8

Thanks for pointing that out TB. I replayed the relevant bit several times. Rohan kind of “skimmed” over it without going into detail.

I kind of get the gist of it; mitochondrial dysfunction results in a bioenergetic deficit which manifests as this or that disease/condition. Correct the mitochondrial dysfunction and the condition might be alleviated.

What’s puzzling me is that there are a large number of mutations that could be associated with mitochondrial disorders, even just in the area of eye disease.

So, if PYC produces a RNA therapy for mutation “A”, it should have no effect if the patient has mutation “B through to Z.” And the mutations can be nuclear (in the cell’s genome) or mitochondrial (in the mitochondrial genome).
So it’s multi factorial.

I guess Rohan and the clever researchers at PYC and the external eye doctors have a plan, but, if they do, I wish they’d share it with SH. I want them to stay laser-focused on the existing programs and not start dissipating resources until cash flow is established.